Background/Aims: Recent interest in the use of cannabinoids as therapeutic agents has revealed the involvement of the endogenous cannabinoid system (ECS) in the regulation of the cardiovascular system in hypertension. Abnormalities in glucose metabolism and insulin action are commonly detected in hypertensive animals. Thus, potential antihypertensive drugs should be investigated with respect to modulation of glucose homeostasis. Therefore, the aim of the present study was to evaluate the effects of the ECS activation after chronic fatty acid amide hydrolase inhibitor (URB597) administration on plasma glucose and insulin concentrations as well as parameters of myocardial glucose metabolism in the deoxycorticosterone acetate (DOCA)-salt hypertensive rats, an animal model of secondary hypertension. Methods: Hypertension was induced by DOCA (25mg/kg) injections and addition of 1% NaCl in the drinking water for six weeks. Chronic activation of the ECS was performed by URB597 (1mg/kg) injections for two weeks. We examined fasting plasma levels of insulin (ELISA), glucose and intramyocardial glycogen (colorimetric method). Expressions of glucose transporters (GLUT1, 4) and selected proteins engaged in GLUT translocation as well as glucose metabolism were determined using Western blotting. Results: Hypertension induced hypoinsulinemia with concomitant lack of significant changes in glycemia, reduced intramyocardial glycogen content and increased pyruvate dehydrogenase (PDH) expression in the cardiac muscle. Importantly, chronic URB597 administration in the hypertensive rats increased insulin concentration, elevated plasmalemmal GLUT1 and GLUT4 expression and concomitantly improved myocardial glycogen storage. Conclusion: Chronic administration of fatty acid amide hydrolase (FAAH) inhibitor has potential protective properties on myocardial glucose metabolism in hypertension.
Introduction
Long chain fatty acids (LCFA) and glucose are the major energy substrates of the myocardium, which supply nearly 80% and 20% of ATP, respectively. The uptake of both substrates is controlled mostly by plasma membrane protein transporters [1] . It is known that glucose transport is regulated by glucose transporters 1 and 4 (GLUT1 and GLUT4) in the cardiomyocytes [2] . GLUT1 is an insulin-independent glucose transporter responsible for basal glucose transport [3, 4] . In contrast, GLUT4 is translocated to the cell surface in response to insulin [1] , ischemia or cardiac overload [5] . Importantly, total expression and translocation of glucose transporters from an intracellular depot to the plasma membrane adjusts glucose influx to the current myocardial energy demands [5] .
Hypertension is one of the most common diseases of civilization. Interestingly, glucose intolerance and insulin resistance have been recently reported for patients with hypertension [6] . Moreover, there is a growing body of evidence that indicates a shift in myocardial energy substrate preference from LCFA to glucose in hypertension [7, 8] . This suggests that high blood pressure is a relevant factor affecting not only whole-body, but also myocardial energy metabolism.
There is a large variety of drugs lowering blood pressure, however, current strategies have not been successful in the treatment of different types of hypertension. Recently, there has been renewed interest in the use of cannabinoids for therapeutic purposes and their effects on the endogenous cannabinoid system (ECS). This system is composed of arachidonate-based ligands, such as anandamide (AEA), which exert their effects by interacting with metabotropic cannabinoid receptors 1 and 2 (CB 1 and CB 2 ) [9] . It should be mentioned that fatty acid amide hydrolase (FAAH) is an enzyme, which is responsible for AEA degradation and, therefore, determines endocannabinoids activity in the tissues [10] . Interestingly, studies have shown that both, acute and chronic pharmacological FAAH inhibition by (30-(aminocarbonyl) [1, 10- biphenyl]-3-yl)-cyclohexylcarbamate (URB597) administration normalized elevated blood pressure [11, 12] . Since the ECS controls energy homeostasis [13] we wanted to determine whether decreased FAAH activity would have an impact on cardiac metabolism.
Therefore, the purpose of this study was to examine the effects of the ECS activation, after chronic inhibition of FAAH (URB597 treatment) in the hypertensive rats, on myocardial glucose metabolism. In our research we conducted experiments on the deoxycorticosterone acetate (DOCA)-salt rats, a commonly used animal model of secondary hypertension [14] [15] [16] [17] . We have assessed parameters of myocardial glucose metabolism, including total expression and subcellular redistribution of glucose transporters, expression of key enzymes involved in glycolysis metabolic pathway and Krebs cycle, proteins engaged in GLUT translocation as well as intramyocardial glycogen content. Moreover, plasma levels of insulin and glucose were measured in this study along with insulin sensitivity indexes.
Materials and Methods
Source of chemicals DOCA, dimethyl sulfoxide (DMSO) and N,N-dimethylformamide (DMF) were purchased from SigmaAldrich (Steinheim, Germany). 30-(aminocarbonyl)[1, 10-biphenyl]-3-yl)-cyclohexylcarbamate (URB597), Glucose Assay Kit (ab65333) and Glycogen Colorimetric Assay Kit II (Catalog #K648-100) were obtained from Cayman Chemical Company (Ann Arbour, MI, USA), Abcam (Cambridge, UK) and BioVision Inc. (Milpitas, CA, USA), respectively. Mercodia Rat Insulin ELISA (10-1250-01) were received from Mercodia AB (Uppsala, Sweden). Antibodies were obtained from following sources: anti-AMPK (#2532), anti-phospho-AMPK (#2535S), anti-AKT (#4691L), anti-phospho-AKT (#9271S), anti-p44/42 MAPK (anti-MAPK3/1) (#9102), anti-phospho-p44/42 MAPK (anti-phospho-MAPK3/1) (#4377S) -Cell Signalling Technology (Danvers, MA, USA), anti-GAPDH (sc-32233), anti-GLUT1 (sc-7903), anti-GLUT4 (sc-53566) and anti-Na
Experimental model of DOCA-salt hypertension The rats were randomly divided into four groups of 6 rats each: (I) CONTROL: normotensive, control rats; (II) URB597: normotensive rats treated with URB597; (III) DOCA-salt: hypertensive rats; (IV) DOCA-salt + URB597: hypertensive rats treated with URB597. Right uninephrectomy was performed on all rats. The animals were anaesthetized with intraperitoneal injection of pentobarbitone sodium (300 μmol/kg body weight). The kidney was visualized by a right lateral abdominal incision and right renal artery. Then, the ureter was ligated by silk thread and the right kidney was removed. After 7 days of recovery, rats were divided into two groups: normotensive and hypertensive. Rats from the normotensive group received subcutaneous injections of DOCA solvent -DMF (N,N-dimethylformamide) twice a week for six consecutive weeks and tap water to drink. Simultaneously, the hypertensive rats were given 1% NaCl in the drinking water with concomitant injections of DOCA (25 mg/kg [18] [19] [20] [21] in 0.4 ml/kg DMF). After 4 weeks, half of the normotensive and half of the hypertensive animals were injected with URB597 (1mg/ml/kg) twice a day for the next 2 weeks [12, 22, 23] . At the same time the rest of rats received URB597 solvent -DMSO (1 ml/kg; Tween 80 and 0.9% NaCl (1:2:7)). In some studies URB597 is used at a dose of 0.3 mg/kg [24] , which may reduce endocannabinoid-induced effects [25] . Moreover, it was demonstrated that chronic URB597 injections at a dose of 1 mg/kg enhanced AEA levels and exhibited anti-inflammatory properties [26] as well as anti-nociceptive and anxiolytic-like activity [27] . It should be also mentioned that the short half-life span of URB597 limits its chronic use [24] . Therefore, URB597 therapy is more effective (e.g. in arthritis severity) when the dose frequency is increased from one to two times a day [28] .
Moreover, hemodynamic parameters, body and heart weights as well as cardiomyocytes dimension were monitored throughout the study and included in our previous article [29] . Briefly, induction of DOCAsalt hypertension caused a significant increase in mean blood pressure (MBP, +42.9% vs control group) value.
Collection of samples
Twelve hours after the last dose of URB597 or its solvent, rats were sacrificed under pentobarbitone sodium anaesthesia. Then, samples of the left ventricle were excised and immediately frozen in liquid nitrogen. Moreover, blood samples were collected in heparinized tubes, centrifuged and the plasma was separated. All samples were stored at -80˚C for further analysis.
Plasma measurements
Fasting plasma glucose (FPG) concentration was determined with the use of Glucose Assay Kit (Abcam, Cambridge, UK), as specified by the manufacturer. Briefly, glucose was measured by incubating samples with appropriate reaction mix for 30 minutes at 37˚C. During incubation glucose was oxidized generating a colourful product. The absorbance was measured at 570nm. Glucose concentration was expressed in nanomoles per microlilter of sample. Moreover, fasting plasma insulin (FPI) concentration was determined using Rat Insulin ELISA Kit (Mercodia AB, Uppsala, Sweden). Insulin concentration was measured at 450nm and expressed in microunits per milliliter. Intra-and inter-assay coefficients of variations were less than 3.7% and less than 5.8%, respectively. The values were calculated on the basis of a standard curve constructed for Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry each assay. At the end of each measurement the intensity of coloured products was measured in a hybrid multi-mode microplate reader (Synergy H1 TM , BioTek Instruments, Winooski, VT, USA). We also evaluated insulin sensitivity indexes (validated in Wistar rats [30] ): the homeostasis model assessment of insulin resistance (HOMA-IR = (FPG x FPI)/2, 430), the quantitative insulin sensitivity check index (QUICKI = 1/[log(FPG) + log(FPI)]) and the fasting glucose/insulin ratio (FGIR = FPG/FPI), where FPG was expressed in milligrams per deciliter and FPI in microunits per milliliter in each equation.
Intramyocardial glycogen analysis
The glycogen content was determined using a colorimetric method (Glycogen Colorimetric Assay Kit II, BioVision Inc., Milpitas, CA, USA) following manufacturer's protocol. In brief, samples of the left ventricle were homogenized in glycogen hydrolysis buffer and centrifuged. Collected supernatants were diluted 20 times prior to adding development enzyme mix. After incubation, absorbance of glycogen products was measured at 450nm using a hybrid multi-mode microplate reader (Synergy H1 TM , BioTek Instruments, Winooski, VT, USA). Determinations of unknown concentrations of samples were based on standard curve. Glycogen concentration was expressed in micrograms per microliter of sample.
Subcellular fractionation of cardiac myocytes
Subcellular fractionation of the cardiac myocytes was performed to examine changes in the expression of GLUT1 and GLUT4 at the level of plasma membranes (PM) and low density microsomes (LDM). Isolation of PM and LDM was carried out according to Fuller et al. method [31] , with modifications described in details by Kalinowska et al. [32] . The purity of isolated fractions was evaluated by Western blotting using appropriate markers, i.e. ATPase sodium/potassium pump (Na + /K + pump) for plasma membranes and sarcoplasmic/endoplasmic reticulum calcium ATPase for endosomal membranes (SERCA). Plasmalemmal and intramyocellular protein expression was normalized to Na + /K + pump or SERCA expression, respectively.
Western blotting
For detecting total, plasmalemmal and intramyocellular protein expression Western blotting procedure was used, as it was described [33] . Briefly, bichinchoninic acid (BCA) method with bovine serum albumin (BSA) as a standard was applied for protein concentration determination. Samples were subjected to 10% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis and wet transfer. Next, the membranes were blocked in Tris Buffer Saline Tween20 (TBST; 20mM Tris, 150mM NaCl, 0.1% Tween20) containing 5% (wt/vol) non-fat dry milk or BSA. Thereafter, the membranes were incubated with primary antibodies overnight, diluted in TBST: citrate synthase (CS; 1:1000), protein kinase B (AKT; 1:1000), phosphorylated AKT (phospho-AKT; 1:1000), AMP-activated protein kinase (AMPK; 1:1000), phosphorylated AMPK (phospho-AMPK; 1:1000), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:500), GLUT1 (1:500), GLUT4 (1:500), mitogen-activated protein kinase (p44/42 MAPK; MAPK3/1; 1:1000), phosphorylated MAPK (phospho-p44/42 MAPK; phospho-MAPK3/1; 1:1000) and pyruvate dehydrogenase (PDH; 1:1000). Then, the membranes were washed and incubated with appropriate secondary antibodies conjugated with horseradish peroxidase and diluted (1:3000) in TBST. The examined proteins were visualized using an enhanced chemiluminescence substrate and obtained signals were quantified by densitometry (ChemiDoc visualization system, Bio Rad, Warsaw, Poland). Routine Ponceau S staining was used to confirm equal protein loading in each lane (30 µg). Protein expression was standardized to GAPDH expression. Experimental groups were expressed relative to the control group, which was set as 100%.
Immunohistochemical analysis
In the immunohistochemical (IHC) study, the EnVision method was used according to Herman and Elfont [34] . Before commencing IHC staining for GLUT1 and GLUT4 recommended antigen retrieval was performed using Target Retrieval Solution pH=9.0 (S2367; Dako, Dennmark). Thereafter tissues were blocked in Peroxidase Blocking Reagent (S 2001 Dako Denmark A/S, Produktionsvej 42, DK-2600 Glostrup) for 10 minutes at room temperature. Sections were incubated with primary antibodies i.e. GLUT1 and GLUT4 for 1 hour in room temperature. HRP polymer KIT was used as the secondary antibody for 30 minutes followed by colorimetric detection using chromogen DAB. Sections were counterstained with hematoxilin and dehydrated with pure ethanol and xylene to prepare for mounting. The obtained results of immunohistochemical staining were submitted for evaluation on an Olympus BX41 microscope with an Cellular Physiology and Biochemistry
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Olympus DP12 camera under a magnification of 200x (20x lens and 10x eyepiece). Morphometric analysis of images was performed using NIS-Elements Advanced Research software of Nikon. The intensity of the immunohistochemical reaction was measured using a 0 to 256 grey scale level in ten randomly selected sites of each rat's heart, in which white or bright pixels received a value of 0 and a completely black pixels were given a value of 256.
Statistical analysis
All presented data are expressed as mean values ± SD and based on six independent rats. Statistical differences between groups were tested with two-way analyses of variance (ANOVA) and appropriate post hoc tests using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). Statistical significance level was set at P<0.05.
Results

Effect of prolonged activation of the ECS on plasma glucose and insulin concentrations and insulin sensitivity indexes in the DOCA-salt hypertension
Induction of DOCA-salt hypertension significantly reduced plasma insulin concentration and HOMA-IR in rats (-68.7% and -68.2%, P<0.05, Fig. 1b 
Effect of prolonged activation of the ECS on the myocardial glycogen content in the DOCAsalt hypertension
We recorded a marked decrease in the content of glycogen in the left ventricle in the DOCA-salt group in comparison with the normotensive group (-44.1%, P<0.05, Fig. 1c) . Interestingly, chronic URB597 administration significantly increased intramyocardial glycogen level in the DOCA-salt rats compared to the hypertensive group alone (+47.3%, P<0.05, Fig. 1c ). Additionally, a trend toward decrease in the cardiac glycogen stores was observed in the normotensive rats after chronic FAAH inhibition compared to the normotensive group (-27.6%, P=0.19, Fig. 1c) .
Effect of prolonged activation of the ECS on the myocardial total and subcellular expression of glucose transporters in the DOCA-salt hypertension
We observed that the total expression of both glucose transporters remained unchanged in all examined groups and only chronic FAAH inhibition significantly elevated plasmalemmal expression of GLUT1 as well as GLUT4 (+29.2% and +28.5%, P<0.05, Fig. 2b,d, respectively; vs. normotensive group) in the hypertensive rats. 
Effect of prolonged activation of the ECS on the myocardial total expression of PDH, CS, phospho-AKT, AKT, phospho-p44/42 MAPK, p44/42 MAPK, phospho-AMPK, and AMPK in the DOCA-salt hypertension
Induction of hypertension in the DOCA-salt rats resulted in a significant increase in the myocardial PDH expression in comparison with the normotensive control group (+30.1%, P<0.05, Fig. 5a ). Nonetheless, PDH expression in the hypertensive group after the ECS activation was still elevated in comparison with the normotensive group alone as well as treated with URB597 (+31.1% and +14.1%, P<0.05, Fig. 5a, respectively) . Moreover, 
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there was a considerable increase in the myocardial CS expression in the DOCA-salt rats after chronic FAAH inhibition in comparison with both the URB597 untreated and treated normotensive groups (+21.2% and +18.9%, P<0.05, Fig. 5b, respectively) .
Discussion
DOCA-salt-induced hypertension.
In the present study we examined the effect of DOCA-salt induction of hypertension on the myocardial glucose metabolism. It is well known that insulin has a significant impact on the metabolism of insulin-sensitive tissues by promoting the absorption of glucose from the blood into the cells, including cardiomyocytes. In our study the DOCA-salt rats had substantially reduced plasma insulin concentration, which was in line with previous findings [20, 35, 36] . Ndisang et al. revealed presence of severe inflammation and fibrosis in the pancreatic tissue in the DOCA-salt rats, which might be the cause of decreased insulinproducing capability of β-cells [36] . Interestingly, as in others [20, 36] , also in our study depressed circulating insulin level was not coupled with hyperglycemia in the DOCA-salt rats, thus glucose availability for the heart remained unchanged. Therefore, we investigated whether DOCA-salt hypertension had an influence on insulin sensitivity indexes. The DOCAsalt rats had significantly lower values of HOMA-IR and simultaneously greater QUICKI as well as FGIR indexes, which may indicate that increased tissue insulin sensitivity was compensating reduced plasma insulin level. Consequently, it is possible that glucose influx into the cells could be stable.
Moreover, it is well established that the rate of glucose metabolism depends on glucose transport related to the number of special carrier proteins (in the heart especially GLUT1 and GLUT4). In our study the total and subcellular expression of both transporters as well as phosphorylation of proteins engaged in glucose transporters translocation (AKT, p44/42-MAPK, AMPK) were unchanged in the DOCA-salt heart homogenates, which may suggest that the transport rate was not altered. In addition, lack of differences in the total GLUT4 expression in the DOCA-salt rat hearts was consistent with the results obtained by Atkins et al. [37] . It is likely that enhanced needs for energy production in the pressure-overloaded heart [38] was not followed by alterations in the total glucose transporters expression as well as their intracellular translocation. However, increased workload resulted in decreased intramyocardial glycogen content, as it was confirmed also by Coprean et al. [39] . Likewise, this phenomenon was demonstrated in the cardiomyocytes of DOCA-salt rats in the presence of glucose in the incubation medium [39] . These data suggest that glycogen is an important carbohydrate source for the heart in hypertension. On the other hand, low insulin level in the DOCA-salt hypertension observed in our study can explain intensified myocardial glycogen depletion [40] . It is likely that the above mentioned alterations might reflect a switch in the hypertensive state towards increased glucose utilization in the cardiomyocytes [41] . It is not surprising because 10% more ATP is generated from glycolysis than fatty acid oxidation per mole of oxygen [42] . Thus, glucose is more effective source of energy when heart is subjected to higher work (such as in hypertension), especially in hypertrophied heart [43] , which was also present in our model and described previously [29] . Moreover, elevated myocardial expression of PDH in our study might reveal that in hypertension, pyruvate was mainly converted into acetyl-Co-A linking the glycolysis pathway to the Krebs cycle, which takes place only in aerobic conditions. Therefore, it indicates on enhanced myocardial glycolysis rate in the DOCA-salt rats.
Effects of URB597 chronic administration in the normotensive hearts
Prolonged activation of the ECS in our study had no effect on either glycaemia or insulin sensitivity indexes, although a trend for decreased plasma insulin concentration in the normotensive rats after chronic FAAH inhibition was observed. Others also noted that URB597 did not change fasting glucose concentration in the normotensive WKY rats [44] . In contrary, Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the latest reports indicate that URB597 may affect plasma glucose level in the WKY rat strain but only non-fasting stage [23, 45] . Interestingly, recent studies provide contradictory data regarding the effects of the ECS stimulation on insulin secretion from β cells and plasma insulin concentration [46] [47] [48] [49] [50] . Accordingly, Anderson et al. [51] revealed that inhibition of FAAH with URB597, as in our study, did not alter basal as well as glucose-induced insulin release from isolated islets of Langerhans. While Rivera et al. [23] reported that WKY rats had lower basal insulin concentration in plasma. Therefore, the exact mechanism of the ECS action (FAAH inhibition) on insulin secretion still remains unknown. Our data indicate that chronic URB597 application in the normotensive rats did not affect cardiac metabolism, since all examined parameters of myocardial glucose homeostasis were unchanged compared to the normotensive control group (Fig. 3-5) .
Effects of URB597 chronic administration in the DOCA-salt hearts
In our study prolonged activation of the ECS by URB597 treatment partially restored plasma insulin level in the DOCA-salt hypertensive rats, which was not accompanied by a change in glycemia. This observation is especially interesting since some antihypertensive agents exhibit adverse effects on glucose homeostasis inducing e.g. hyperglycaemia, insulin resistance or diabetes mellitus, which might be linked with future cardiovascular disorders [52] .
It is well established that insulin promotes both translocation of glucose transporters [53] and glycogen synthesis in the heart. Therefore, it is possible that restored insulin concentration was, at least to some extent, responsible for increased presence of glucose transporters (GLUT4) at the plasma membranes. Probably, this insulin-dependent translocation may be the consequence of increased AKT activity since we observed a trend toward elevated phosphorylation of this kinase after chronic FAAH inhibition. The latest reports indicate that ECS activation by URB597 application may activate AKT signalling in the central nervous system [54, 55] . Although there is no data on URB597 action on AKT pathway in the myocardium, the results of other studies revealed that activation of the ECS by other compounds induced an increase in AKT phosphorylation in the heart [56] [57] [58] .
When hypertension was combined with the ECS activation we observed a statistically significant increase in plasmalemmal glucose transporters expression. This fact demonstrates that the ECS probably takes part in the regulation of heart glucose metabolism in hypertension. Since GLUTs translocation is usually associated with increased glucose influx into cells it is possible that FAAH inhibition improved cardiomyocytes glucose supply [59] . As a result myocardial glycogen content was restored compared to the DOCA-salt group alone. We may speculate that restoring glycogen levels in the DOCA-salt rats heart may have a cardioprotective role since others have shown that greater myocardial glycogen content protects the heart against hypoxia [60] and lowers the incidence of complications in patients after bypass surgery [61] . It was also shown that glycogen depletion occurs in several heart disorders [62] [63] [64] and, additionally, the absence of myocardial glycogen is associated with abnormal cardiac development in a mouse model of muscle glycogen synthase knockout [65] . Furthermore, as in the hypertensive group alone, after prolonged ECS activation intensified myocardial glycolysis was noticed (elevated PDH expression) in the DOCA salt rats. However, it does not appear to be a result of the ECS activation, since myocardial PDH expression remained unchanged in spite of URB597 application in the hypertensive rats. Interestingly, expression of routinely used metabolic marker of aerobic capacity and mitochondrial function, CS [66, 67] , was increased, which indicates that ECS activation in the hypertensive rats may support mitochondrial energy generation in the cardiac muscle.
Conclusion
The present study describes the effects of induced hypertension together with ECS activation on myocardial glucose metabolism. We found that hypertensive status in the
